Utility of drug-eluting stents in complex lesions and high-risk patients

Article

Opinion statement

Drug-eluting stents represent a breakthrough technology designed to deliver high concentrations of a bioactive agent locally to an atherosclerotic lesion, thereby minimizing systemic side effects of the drug. The safety and efficacy of drug-eluting stents have clearly been demonstrated in noncomplex lesions. This article presents an evidence-based analysis of the current experience with CYPHER sirolimus-eluting stents (Cordis Corp., Miami Lakes, FL) and TAXUS paclitaxel-eluting stents (Boston Scientific, Natick, MA) in a broad spectrum of high-risk and/or complex subsets of patients and lesions, including those with diabetes mellitus, multivessel disease, diffuse disease, very small vessels, lesions in saphenous vein grafts, chronic total occlusions, in-stent restenosis, ostial and bifurcation lesions, unprotected left main disease, and acute myocardial infarction. Emerging data in several of these subsets suggest that drug-eluting stents are safe and effective, and their use may currently be recommended, whereas in other groups of patients and lesions the efficacy and/or safety of drug-eluting stents remains to be determined, thus warranting caution. It is anticipated that penetration of drug-eluting stents will continue to increase, and fewer patients will require surgical revascularization to achieve sustained event-free survival.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Morice MC, Serruys PW, Sousa JE, et al.: Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773–1780.PubMedCrossRefGoogle Scholar
  2. 2.
    Colombo A, Drzewiecki J, Banning A, et al.: Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108:788–794.PubMedCrossRefGoogle Scholar
  3. 3.
    Moses JW, Leon MB, Popma JJ, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315–1323.PubMedCrossRefGoogle Scholar
  4. 4.
    Stone GW, Ellis SG, Cox DA, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221–231.PubMedCrossRefGoogle Scholar
  5. 5.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. N Engl J Med 1996, 335:217–225.Google Scholar
  6. 6.
    Stein B, Weintraub WS, Gebhart SP, et al.: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995, 91:979–989.PubMedGoogle Scholar
  7. 7.
    Abizaid A, Costa MA, Centemero M, et al.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Circulation 2001, 104:533–538.PubMedCrossRefGoogle Scholar
  8. 8.
    Niles NW, McGrath PD, Malenka D, et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001, 37:1008–1015.PubMedCrossRefGoogle Scholar
  9. 9.
    Moussa I, Leon MB, Baim DS, et al.: Impact of sirolimuseluting stents on outcome in diabetic patients: a SIRIUS (SIRolIm US-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109:2273–2278.PubMedCrossRefGoogle Scholar
  10. 10.
    Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, et al.: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. Circulation 2005, 112:2175–2183.PubMedCrossRefGoogle Scholar
  11. 11.
    Hermiller JB, Raizner A, Cannon L, et al.: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005, 45:1172–1179.PubMedCrossRefGoogle Scholar
  12. 12.
    Dibra A, Kastrati A, Mehilli J, et al.: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005, 353:663–670.PubMedCrossRefGoogle Scholar
  13. 13.
    Windecker S, Remondino A, Eberli FR, et al.: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005, 353:653–662.PubMedCrossRefGoogle Scholar
  14. 14.
    Morice MC: REALITY: Prospective, Randomized, Multicenter Head-to-Head Comparison of Cypher and Taxus Stent Systems. Paper presented at the American College of Cardiology 2005 Annual Scientific Session. Orlando, FL; March 6–9, 2005.Google Scholar
  15. 15.
    Cosgrave J, Agostoni P, Ge L, et al.: Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 2005, 96:1663–1668.PubMedCrossRefGoogle Scholar
  16. 16.
    Ong AT, Aoki J, van Mieghem CA, et al.: Comparison of short-(one month) and long-(twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005, 96:358–362.PubMedCrossRefGoogle Scholar
  17. 17.
    Doucet S, Schalij MJ, Vrolix MC, et al.: Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001, 104:2029–2033.PubMedGoogle Scholar
  18. 18.
    Hausleiter J, Kastrati A, Mehilli J, et al.: Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial. Am J Cardiol 2002, 89:58–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Nikolsky E, Moses JW, Cambier P, et al.: Results from the 2.25 mm Sirolimus-Eluting BX VelocityTM Stent Registry in patients with native coronary artery lesions. Transcatheter Cardiovascular Therapeutics, Washington, September 2005. Am J Cardiol 2005, 96(suppl 7):456.Google Scholar
  20. 20.
    Schofer J, Schluter M, Gershlick AH, et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362:1093–1099.PubMedCrossRefGoogle Scholar
  21. 21.
    Schampaert E, Cohen EA, Schluter M, et al.: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004, 43:1110–1115.PubMedCrossRefGoogle Scholar
  22. 22.
    Sousa JE: SVELTE: Study in Patients with De Novo Coronary Artery Lesions in Small Vessels Treated With the Cypher Stent. Paper presented at the EuroPCR 2004, the Paris Course on Revascularization. Paris, France: May 25–28, 2004.Google Scholar
  23. 23.
    Ardissino D, Cavallini C, Bramucci E, et al.: Sirolimuseluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004, 292:2727–2734.PubMedCrossRefGoogle Scholar
  24. 24.
    Mehilli J, Dibra A, Kastrati A, et al.: Randomized trial of paclitaxel-and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006, 27:260–266.PubMedCrossRefGoogle Scholar
  25. 25.
    Stone GW, Ellis SG, Cannon L, et al.: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005, 294:1215–1223.PubMedCrossRefGoogle Scholar
  26. 26.
    Tsagalou E, Chieffo A, Iakovou I, et al.: Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005, 45:1570–1573.PubMedCrossRefGoogle Scholar
  27. 27.
    Dawkins KD, Grube E, Guagliumi G, et al.: Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005, 112:3306–3313.PubMedCrossRefGoogle Scholar
  28. 28.
    Buller CE, Dzavik V, Carere RG, et al.: Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999, 100:236–242.PubMedGoogle Scholar
  29. 29.
    Hoher M, Wohrle J, Grebe OC, et al.: A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol 1999, 34:722–729.PubMedCrossRefGoogle Scholar
  30. 30.
    Lotan C, Rozenman Y, Hendler A, et al.: Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J 2000, 21:1960–1966.PubMedCrossRefGoogle Scholar
  31. 31.
    Rahel BM, Suttorp MJ, Laarman GJ, et al.: Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J 2004, 147:e22.PubMedCrossRefGoogle Scholar
  32. 32.
    Stone GW, Kandzari DE, Mehran R, et al.: Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005, 112:2364–2372.PubMedCrossRefGoogle Scholar
  33. 33.
    Stone GW, Reifart NJ, Moussa I, et al.: Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005, 112:2530–2537.PubMedCrossRefGoogle Scholar
  34. 34.
    Suttorp MJ: Prospective Randomized Trial of Sirolimus-Eluting and Bare Metal Stents in Patients with Chronic Total Occlusions. (PRISON II). Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  35. 35.
    Werner GS, Schwarz G, Prochnau D, et al.: Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv 2006, 67:1–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Lefevre T, Louvard Y, Morice MC, et al.: Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv 2000, 49:274–283.PubMedCrossRefGoogle Scholar
  37. 37.
    Al Suwaidi J, Yeh W, Cohen HA, et al.: Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001, 87:1139–1144.PubMedCrossRefGoogle Scholar
  38. 38.
    Colombo A: Balloon crush: new tool in bifurcation treatment armamentarium. Catheter Cardiovasc Interv 2004, 63:417–418.PubMedCrossRefGoogle Scholar
  39. 39.
    Colombo A, Moses JW, Morice MC, et al.: Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004, 109:1244–1249.PubMedCrossRefGoogle Scholar
  40. 40.
    Pan M, de Lezo JS, Medina A, et al.: Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J 2004, 148:857–864.PubMedCrossRefGoogle Scholar
  41. 41.
    Tanabe K, Hoye A, Lemos PA, et al.: Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 2004, 94:115–118.PubMedCrossRefGoogle Scholar
  42. 42.
    Ge L, Airoldi F, Iakovou I, et al.: Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. Am Coll Cardiol 2005, 46:613–620.CrossRefGoogle Scholar
  43. 43.
    Mercado N, Wijns W, Serruys PW, et al.: One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005, 130:512–519.PubMedCrossRefGoogle Scholar
  44. 44.
    Serruys PW, Unger F, Sousa JE, et al.: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117–1124.PubMedCrossRefGoogle Scholar
  45. 45.
    Schonberger JP, Buller N, Bonser R, et al.: Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005, 46:575–581.PubMedCrossRefGoogle Scholar
  46. 46.
    Serruys PW, Lemos PA, van Hout BA: Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 2004, 90:995–998.PubMedCrossRefGoogle Scholar
  47. 47.
    Mikhail GW, Airoldi F, Tavano D, et al.: The use of drug eluting stents in single and multivessel disease: results from a single centre experience. Heart 2004, 90:990–994.PubMedCrossRefGoogle Scholar
  48. 48.
    Park SJ, Kim YH, Lee BK, et al.: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005, 45:351–356.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee SH, Ko YG, Jang Y, et al.: Sirolimus-versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis. Cardiology 2005, 104:181–185.PubMedCrossRefGoogle Scholar
  50. 50.
    Valgimigli M, van Mieghem CA, Ong AT, et al.: Short-and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005, 111:1383–1389.PubMedCrossRefGoogle Scholar
  51. 51.
    Chieffo A, Stankovic G, Bonizzoni E, et al.: Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005, 111:791–795.PubMedCrossRefGoogle Scholar
  52. 52.
    de Lezo JS, Medina A, Pan M, et al.: Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J 2004, 148:481–485.PubMedCrossRefGoogle Scholar
  53. 53.
    Gershlick A, Guagliumi G, Guyon P, et al.: Sirolimus eluting stent and unprotected left main stenosis: the multicenter e-cypher registry [abstract]. Heart 2005, 91:a5–i72.Google Scholar
  54. 54.
    Lee MS, Kapoor N, Jamal F, et al.: Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006, 47:864–870.PubMedCrossRefGoogle Scholar
  55. 55.
    Price MJ, Cristea E, Sawhney N, et al.: Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol 2006, 47:871–877.PubMedCrossRefGoogle Scholar
  56. 56.
    Buszman P: Acute and late outcome of unprotected left main stenting in comparison with surgical revascularization. The LE MANS trial. Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  57. 57.
    Teirstein PS, Massullo V, Jani S, et al.: Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000, 101:360–365.PubMedGoogle Scholar
  58. 58.
    Waksman R, White RL, Chan RC, et al.: Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000, 101:2165–2171.PubMedGoogle Scholar
  59. 59.
    Waksman R, Cheneau E, Ajani AE, et al.: Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation 2003, 107:1744–1749.PubMedCrossRefGoogle Scholar
  60. 60.
    Leon MB, Teirstein PS, Moses JW, et al.: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001, 344:250–256.PubMedCrossRefGoogle Scholar
  61. 61.
    Neumann FJ, Desmet W, Grube E, et al.: Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005, 111:2107–2111.PubMedCrossRefGoogle Scholar
  62. 62.
    Tanabe K, Serruys PW, Grube E, et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003, 107:559–564.PubMedCrossRefGoogle Scholar
  63. 63.
    Alfonso F, Angel J, Cequier A, et al.: Results of the restenosis intrastent: balloon angioplasty versus rapamycin-eluting stent implantation randomized study [abstract]. J Am Coll Cardiol 2005, 45:83A.Google Scholar
  64. 64.
    Kastrati A, Mehilli J, von Beckerath N, et al.: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005, 293:165–171.PubMedCrossRefGoogle Scholar
  65. 65.
    Holmes DR: Sirolimus-Eluting Stent vs. Brachytherapy in Patients With Bare Metal In-Stent Restenosis (SISR). Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington, DC; October 16–21, 2005.Google Scholar
  66. 66.
    Stone GW, Ellis SG, O’shaughnessy CD, et al.: Paclitaxeleluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents. The TAXUS V ISR randomized trial. JAMA 2006, 295:1253–1263.PubMedCrossRefGoogle Scholar
  67. 67.
    Waskman R: How to manage drug-eluting stent in-stent restenosis. Paper presented at the the EuroPCR 2005. Paris, France; May 24–27, 2005.Google Scholar
  68. 68.
    Cheneau E, John MC, Fournadjiev J, et al.: Time course of stent endothelialization after intravascular radiation therapy in rabbit iliac arteries. Circulation 2003, 107:2153–2158.PubMedCrossRefGoogle Scholar
  69. 69.
    de Jaegere PP, van Domburg RT, Feyter PJ, et al.: Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996, 28:89–96.PubMedCrossRefGoogle Scholar
  70. 70.
    Savage MP, Douglas JS Jr, Fischman DL, et al.: Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997, 337:740–747.PubMedCrossRefGoogle Scholar
  71. 71.
    Hoye A, Lemos PA, Arampatzis CA, et al.: Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004, 16:230–233.PubMedGoogle Scholar
  72. 72.
    Ge L, Iakovou I, Sangiorgi GM, et al.: Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005, 45:989–994.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee MS, Shah AP, Aragon J, et al.: Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005, 66:507–511.PubMedCrossRefGoogle Scholar
  74. 74.
    Chu WW, Rha SW, Kuchulakanti PK, et al.: Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006, 97:34–37.PubMedCrossRefGoogle Scholar
  75. 75.
    Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Stone GW, Grines CL, Cox DA, et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957–966.PubMedCrossRefGoogle Scholar
  77. 77.
    Lemos PA, Saia F, Hofma SH, et al.: Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004, 43:704–708.PubMedCrossRefGoogle Scholar
  78. 78.
    Valgimigli M, Percoco G, Malagutti P, et al.: Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005, 293:2109–2117.PubMedCrossRefGoogle Scholar
  79. 79.
    Grines CL, Cox DA, Stone GW, et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999, 341:1949–1956.PubMedCrossRefGoogle Scholar
  80. 80.
    Laarman GJ: PASSION: Primary PCI is the most effective reperfusion therapy for acute myocardial infarction. Paper presented at the Transcatheter Cardiovascular Therapeutics. Washington DC; October 16–21, 2005.Google Scholar
  81. 81.
    Kernis SJ, Cohen D, Reid K, et al.: Clinical outcomes associated with drug-eluting stents compared with bare-metal stents for primary percutaneous intervention [abstract]. Am J Cardiol 2005, 96:47H.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Herbert Irving PavilionColumbia University Medical CenterNew YorkUSA

Personalised recommendations